Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HELICOVAXOR

Financiado

Cerrado

Development of an oral Helicobacter Pylori vaccine

Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exis... ver más

31/12/2014

SUBLIMITY

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

SUBLIMITY THERAPEUTICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-12-31 No tenemos la información de la convocatoria

0% 72% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

SUBLIMITY

0.00€ | Lider

MEDITOX

N.D. | Participante

UGOT - GOETEBORGS UNIVERSITE...

N.D. | Participante

ALMAC

N.D. | Participante

Proyectos interesantes

Vax2Muc

Medical Technol...

Vaccinology

8M€ Cerrado

Capsulight

Medical Technol...

Biotechnology

71K€ Cerrado

LACTOBODY

Medical Technol...

Biotechnology

6M€ Cerrado

CerviVax

Medical Technol...

Biotechnology

71K€ Cerrado

SHIGETECVAX

Medical Technol...

Biotechnology

9M€ Cerrado

HELICOMARK

Medical Technol...

Data Science

390K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

SUBLIMITY THERAPEUTICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection. Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness. However, with much greater knowledge of the molecular basis of infection and having learnt lessons from previous vaccine developments, the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine: - Powerful, safe and multivalent antigens - Powerful, safe and multi-acting adjuvants - Powerful, modular and flexible oral vaccine delivery system All three of the above innovative technologies have been proven to be effective in doing what they are required to do, namely: - Antigens – produce antibodies against a number of key H pylori bacterial components - Adjuvants – stimulate the immune cells to produce significant numbers of long lasting antibodies - Delivery – formulate antigens and adjuvants together and target the stomach and intestine This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability. This consortium has assembled leading academic, industrial and regulatory groups, the activities of which will be coordinated to perform analysis of the formulations, efficacy and safety testing of the vaccines and the preparation of a regulatory dossier, all required before the product can enter human clinical studies. If successful in pre-clinical studies, the consortium will work with vaccine companies to progress human studies and launch the product as a vaccine to confer protection from H pylori infection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores